<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327352</url>
  </required_header>
  <id_info>
    <org_study_id>OS-DN-P1b-01</org_study_id>
    <nct_id>NCT01327352</nct_id>
  </id_info>
  <brief_title>Evaluation of the Influence of Food Regimen on Oshadi D Absorption</brief_title>
  <official_title>A Single Center, Non-randomized, Placebo Controlled Study for the Evaluation of the Influence of Food Regimen on Oshadi D Absorption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oshadi Drug Administration</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oshadi Drug Administration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a non-randomized, open label, single dose, placebo control, single center,
      and single arm study in healthy subjects. The study will include one administration of
      placebo and four single administrations of Oshadi D in two different dose levels,
      administered in two feeding regimen for the evaluation of the influence of food on Oshadi D
      absorption.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DNase activity level (Kunitz/mL) for 2 dose levels, and different food regimen</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma DNase concentration (ng/mL) in different food regimen and dose levels</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>Oshadi D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 dose levels of Oshadi D in 2 food regimen will be administered as following:
Subjects will receive placebo on the morning of day 1 during fast. Late breakfast will be provided 4 hours following placebo administration.
On day 8 a single dose of 180mg Oshadi D will be administrated during fast. Late breakfast will be provided 4 hours following drug administration
On day 16 subjects will be administered with 360mg of Oshadi D during fast. Late breakfast will be provided 4 hours following drug administration.
On day 24, 180mg of Oshadi D will be administrated immediately after breakfast.
On day 32, subject will be administered with 360mg of Oshadi immediately after breakfast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oshadi D</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Oshadi D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Male/female 21 years old and up.

          -  Subject must understand and be willing to give written informed consent prior to any
             study procedures or evaluations and be willing to adhere to all study schedules and
             requirements.

          -  Subject must be sterile or infertile or use an approved method of contraception from
             the time that the first dose of study medication is taken until three months following
             study completion or discontinuation.

        Exclusion Criteria:

          -  Any history of significant cardiac, renal, neurologic, metabolic, pulmonary,
             gastrointestinal, hematologic abnormality, chronic hepatic disease or any other
             disease which in the judgment of the investigator would interfere with the study or
             confound the results.

          -  Subject with positive HIV serology or positive HBsAg at screening.

          -  History or evidence of any active liver disease.

          -  Female subject who are breastfeeding or have a positive pregnancy test at screening or
             at any time during the study.

          -  Inability to give written informed consent

          -  History of alcohol or drug abuse within 6 months of screening.

          -  Subject who have a positive urine drug screen for substances of abuse (benzodiazepine,
             THC, opiates, amphetamines, cocaine) at the screening.

          -  Mental disorders.

          -  Subject with poor venous access

          -  Significant swallowing disorders

          -  Digestive disorders;

          -  Small bowel surgery;

          -  Mall absorption disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keren Duanis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf Harofe Medical Center, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanna Levy, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Oshadi Drug Administration</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assaf Harofe Medical Center,</name>
      <address>
        <city>Zrifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2011</study_first_submitted>
  <study_first_submitted_qc>March 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <last_update_submitted>June 20, 2012</last_update_submitted>
  <last_update_submitted_qc>June 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lupus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

